New eye drug regimen aims to cut injections for PCV patients
NCT ID NCT07461441
First seen Mar 26, 2026 · Last updated May 01, 2026 · Updated 6 times
Summary
This study tests a personalized treat-and-extend schedule of faricimab for people newly diagnosed with polypoidal choroidal vasculopathy (PCV), a form of age-related macular degeneration. About 50 participants will receive injections, with the goal of safely extending time between treatments to 16 weeks or more. The main focus is on how well the drug controls the disease and improves vision over 96 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Yeungnam university medical center
RECRUITINGDaegu, Namgu, 42415, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.